Home / Stock ratings / DXCM
Stock rating · Surgical & Medical Instruments & Apparatus
DexCom, Inc. (DXCM) Stock Rating & Analysis
As of October 12, 2026, MELANY rates DexCom, Inc. 68 out of 100 (Favorable). Its highest factor score is catalyst setup at 96, and its lowest is valuation at 30.
MELANY ratingRated 2026-10-12DXCM · composite score
About DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetic patients as an alternative to the traditional blood glucose meter process. The company is developing its CGM systems to integrate with insulin pumps from Insulet and Tandem for automatic insulin delivery. Its CGMs are sold through medical equipment distributors and retail pharmacies.
Rating as of 2026-10-12 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why DXCM scores 68/100
DXCM's 8 factor scores run from 30 to 96, and 4 of them sit above its composite of 68. Here is how DXCM breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 61%
- ROE 38%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +13%
- Earnings in 17 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 17 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How DXCM compares
As of October 13, 2026, DexCom, Inc. is tied for 2nd of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 68.
Key risks for DXCM
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
DexCom, Inc. sits in the Healthcare sector theme, which MELANY currently rates 65/100 for strength. Theme strength feeds DXCM's momentum and catalyst factors above.
DXCM trade plan (Pro)
MELANY has a full position plan for DexCom, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates DXCM
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. DexCom, Inc.'s 68/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about DXCM
Is DexCom, Inc. (DXCM) a buy?
As of 2026-10-12, MELANY rated DexCom, Inc. Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is DexCom, Inc.'s MELANY score?
DexCom, Inc. (DXCM) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the DXCM stock rating calculated?
MELANY scores DXCM from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy DexCom, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates DexCom, Inc. (DXCM) Favorable with a composite of 68/100 as of 2026-10-12. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the DXCM stock price forecast?
MELANY does not publish price targets or forecasts for DXCM. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for DexCom, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is DXCM stock overvalued or undervalued?
MELANY's valuation factor currently reads 30/100 for DexCom, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives DXCM's read.
What price should I buy DXCM at?
Rather than chasing the current price, MELANY computes a smart entry zone for DXCM: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying DXCM stock?
The top risks MELANY currently flags for DexCom, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is DexCom, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 84/100 for DexCom, Inc., and earnings track record, at 89/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will DXCM stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 68/100 for DXCM right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this DXCM rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-12. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores DXCM continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, DXCM included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.